Emin Taşkıran1, Oytun Erbaş2, Harun Akar1

1Tepecik Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, Türkiye
2Bilim Üniversitesi Tıp Fakültesi, Fizyoloji Anabilim Dalı, İstanbul, Türkiye

Keywords: Renal transplantation; immunosuppressive agents; immunosuppressive antibody.

Abstract

Newly discovered antibodies combined with standard immunosuppressive agents are preferred for induction of immunosuppression instead of conventional immunosuppressive therapy after renal transplantation. These agents include anti-lymphocyte antibodies (rATG, atgam, alemtuzumab), interleukin 2 receptor antagonists (basiliximab), anti-CD20 antibodies (rituximab). Maintenance immunosuppressive therapy is necessary to prevent acute rejection and loss of allograft. These agents include calcineurin inhibitors (cyclosporine, tacrolimus), corticosteroids (prednisone), antimetabolites (azathioprine, MMF), mTOR inhibitors (sirolimus) and belatacept. Effectiveness and side effects of all regimens will be discussed in the light of previous trials.